Charter Medical Receives 510(k) Clearance For CELL-FREEZE Cryogenic Storage Containers For Peripheral Blood Stem Cells

Lydall, Inc. Charter Medical, Ltd is pleased to announce 510(k) clearance for CELL-FREEZE cryogenic storage containers. CELL-FREEZE cryogenic storage containers were designed for peripherally derived stem cell applications. CELL-FREEZE is used for cryogenic temperature applications as low as -196°C for storage, preservation and transfer.

CELL-FREEZE containers have a uniquely designed proprietary membrane port with attached cap to minimize exposure of the product. CELL-FREEZE containers have pre-attached labels making it easy to include manual information or adhere computer generated labels. CELL-FREEZE containers are available in a range of configurations to fit a variety of freezing systems.

Peter Ferris, President of Charter Medical, Ltd states, "We are excited to introduce CELL-FREEZE cryogenic storage containers for peripheral blood stem cells. This innovative new product leverages Charter Medical's years of expertise in blood transfusion and cell therapy applications."

According to Roberta Morris, Director of Marketing and New Product Development, "CELL-FREEZE with its unique film properties remains flexible down to -196°C making it a perfect storage container for stem cell applications."

Charter Medical, a Lydall company, is part of the Vital Fluid business and manufactures specialty products for the bioprocess and medical device industries.

Charter Medical Ltd headquarters and manufacturing facility are located in Winston-Salem, North Carolina. Learn more about Charter at www.chartermedical.com

Lydall, Inc. is a New York Stock Exchange listed company, headquartered in Manchester, Connecticut. The Company, with operations in the U.S., France, and Germany and sales offices in Europe and Asia, focuses on specialty engineered products for the thermal/acoustical and filtration/separation markets. For additional information, please visit www.lydall.com.

SOURCE: Lydall, Inc.